Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes
Status:
Recruiting
Trial end date:
2022-12-12
Target enrollment:
Participant gender:
Summary
The general aim of this study is to investigate the influence of systemic administration of
Desferal (Deferoxamine [DFO]) on the response to hypoxic challenge in patients with diabetes
mellitus (DM).
The investigation will elucidate if DFO can restore:
- the impaired angiogenetic response to hypoxia in patients with type 1 DM.
- the disturbed respiratory and cardiovascular regulation in response to hypoxia in
patients with DM type 1